scholarly journals A Phase I/II Study of Intrabone Marrow Transplantation of Cord Blood Using Reduced Intensity Conditioning

2016 ◽  
Vol 22 (3) ◽  
pp. S358
Author(s):  
Taizo Tasaka ◽  
Yoshiko Matsuhashi ◽  
Nobuyuki Aotsuka ◽  
Takeshi Kobayashi ◽  
Kazuteru Ohashi ◽  
...  
Keyword(s):  
Phase I ◽  
Cord Blood ◽  
Marrow Transplantation ◽  
Reduced Intensity Conditioning ◽  
Reduced Intensity

scholarly journals Intrabone Marrow Transplantation of Unwashed Cord Blood Using Reduced-Intensity Conditioning Treatment: A Phase I Study

2012 ◽  
Vol 18 (4) ◽  
pp. 633-639 ◽  
Author(s):  
Masaya Okada ◽  
Satoshi Yoshihara ◽  
Kyoko Taniguchi ◽  
Katsuji Kaida ◽  
Kazuhiro Ikegame ◽  
...  
Keyword(s):  
Phase I ◽  
Cord Blood ◽  
Marrow Transplantation ◽  
Phase I Study ◽  
Reduced Intensity Conditioning ◽  
Conditioning Treatment ◽  
Reduced Intensity

A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning

2018 ◽  
Vol 100 (4) ◽  
pp. 335-343 ◽  
Author(s):  
Masaya Okada ◽  
Taizo Tasaka ◽  
Kazuhiro Ikegame ◽  
Nobuyuki Aotsuka ◽  
Takeshi Kobayashi ◽  
...  
Keyword(s):  
Cord Blood ◽  
Phase Ii ◽  
Marrow Transplantation ◽  
Phase Ii Study ◽  
Reduced Intensity Conditioning ◽  
Multicenter Phase ◽  
Reduced Intensity

scholarly journals Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts

Blood ◽  
2011 ◽  
Vol 118 (2) ◽  
pp. 282-288 ◽  
Author(s):  
Claudio G. Brunstein ◽  
Ephraim J. Fuchs ◽  
Shelly L. Carter ◽  
Chatchada Karanes ◽  
Luciano J. Costa ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cord Blood ◽  
Umbilical Cord Blood ◽  
Cumulative Incidence ◽  
Marrow Transplantation ◽  
Phase 2 ◽  
Reduced Intensity Conditioning ◽  
Alternative Donor ◽  
Related Donor ◽  
Reduced Intensity

Abstract The Blood and Marrow Transplant Clinical Trials Network conducted 2 parallel multicenter phase 2 trials for individuals with leukemia or lymphoma and no suitable related donor. Reduced intensity conditioning (RIC) was used with either unrelated double umbilical cord blood (dUCB) or HLA-haploidentical related donor bone marrow (Haplo-marrow) transplantation. For both trials, the transplantation conditioning regimen incorporated cyclophosphamide, fludarabine, and 200 cGy of total body irradiation. The 1-year probabilities of overall and progression-free survival were 54% and 46%, respectively, after dUCB transplantation (n = 50) and 62% and 48%, respectively, after Haplo-marrow transplantation (n = 50). The day +56 cumulative incidence of neutrophil recovery was 94% after dUCB and 96% after Haplo-marrow transplantation. The 100-day cumulative incidence of grade II-IV acute GVHD was 40% after dUCB and 32% after Haplo-marrow transplantation. The 1-year cumulative incidences of nonrelapse mortality and relapse after dUCB transplantation were 24% and 31%, respectively, with corresponding results of 7% and 45%, respectively, after Haplo-marrow transplantation. These multicenter studies confirm the utility of dUCB and Haplo-marrow as alternative donor sources and set the stage for a multicenter randomized clinical trial to assess the relative efficacy of these 2 strategies. The trials are registered at www.clinicaltrials.gov under NCT00864227 (BMT CTN 0604) and NCT00849147 (BMT CTN 0603).

Reduced Intensity Conditioning Regimen for Unrelated Cord Blood Transplantation in Adults. A Multicentric Phase I-II Trial.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3658-3658 ◽  
Author(s):  
Bernard Rio ◽  
Ramdane Belhocine ◽  
Marc Renaud ◽  
Sylvie François ◽  
Eliane Gluckman ◽  
...  
Keyword(s):  
Phase I ◽  
Cord Blood ◽  
Acute Gvhd ◽  
Cord Blood Transplantation ◽  
Reduced Intensity Conditioning ◽  
Hematopoietic Stem ◽  
Neutrophil Recovery ◽  
Unrelated Cord Blood ◽  
Reduced Intensity

Abstract Curative potential of allogeneic transplantation from related or unrelated donors is limited by tranplant related mortality (TRM) and donor compatibility. After reduced intensity conditioning regimens (RIC) transplantation can be extended to older patients, those with poor performance status, organ dysfunction or intensive prior therapy. In absence of HLA-matched donor, unrelated cord blood transplant (UCBT) is a possible source of hematopoietic stem cells. In order to confirm previous report of RIC after UCBT in adults we conducted a phase I–II trial. Primary endpoint was neutrophil recovery and chimerism. Secondary endpoints were early TRM, acute GVHD incidence, early relapse and survival. Between October 2003 and March 2005, 18 patients (pts) were enrolled: median age: 46y (19–64), weight: 62.5 kg(45–90), gender: 13 females and 5 males, CMV serpositivity in 8 pts, ABO major incompatibility in 8 pts. The median of follow-up was 4.5 mo (0.5–16). Disease status were 2 ALL (CR1: 1; CR2: 1), 10 AML (CR1: 3, CR2: 6, CR3: 1), 1 AP CML, 1 CLL, 1 Waldenström disease, 3 follicular lymphoma relapsed after autologous transplantation. Infused nucleated and CD34+ cells number were respectively: 2.3x107/kg (1.7–3.7) and 0.7x105/kg (0.4–1.2). Only a single cord blood was used. HLA disparity was 0/6 in 1, 1/6 in 6 and 2/6 in 11. RIC regimen consisted of cyclophosphamide 50 mg/kg D-6, fludarabine 200 mg/m2 and 2Gy TBI at D-1. CsA and MMF from D-3 were used in GVHD prophylaxis. Pts received GCSF until 5 G ANC/l. Results: Median day for 0.5 G/l ANC recovery was 14 days (0–28) and for 20 G/l platelets was 28 days (0–48). Mixt chimerism was present until D+56 and full chimerism at D+80/100 in all pts except 2 who relapsed. Mucositis was not observed, CMV reactivation in 2 pts, bacteremia in 3, SRV pneumonitis in 1 pt, bone aspergillosis in 1 pt. Regressive limbic encephalitis in 2 pts. Two pts recovered normal ovarian function 5 mo and 12 mo after UCBT. Grade 2 acute GVHD was observed in 2 pts and limited chronic GVHD in 3 out of 8 pts at risk. TRM was 0%. Two pts relapsed and died at D+100 and D+171. EFS was 80+/−13%. In conclusion, in spite of the short follow-up and few patients enrolled in this trial, these results confirm those reported by Barker J et al. Importantly there was a rapid neutrophil recovery with acquired late full chimerism and absence of early TRM. The encouraging results justify the use of cord blood cells in RIC and prospective trials in order to compare phenoidentical peripheral blood stem cell transplantation and UCBT with the same RIC regimen.

Sign in / Sign up

Export Citation Format

Share Document